Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis

Fausto Petrelli, Agostina De Stefani, Francesca Trevisan, Chiara Parati, Alessandro Inno, Barbara Merelli, Michele Ghidini, Lorenza Bruschieri, Elisabetta Vitali, Mary Cabiddu, Karen Borgonovo, Mara Ghilardi, Sandro Barni, Antonio Ghidini

Research output: Contribution to journalReview article

Abstract

Radiotherapy (RT) represents a mainstay in the treatment of brain metastases (BMs) from solid tumors. Immunotherapy (IT) has improved survival of metastatic cancer patients across many tumor types. The combination of RT and IT for the treatment of BMs has a strong rationale, but data on efficacy and safety of this combination is still limited. A systematic search of PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE was conducted. 33 studies were included for a total of 1520 patients, most of them with melanoma (87%). Median pooled OS was 15.9 months (95%CI 13.9–18.1). One- and 2-year OS rates were 55.2% (95% CI 49.3–60.9) and 35.7% (95% CI 30.4–41.3), respectively. Addition of IT to RT was associated with improved OS (HR = 0.54, 95%CI 0.44-0.67; P < 0.001). For patients with BMs from solid tumors, addition of concurrent IT to brain RT is able to increase survival and provide long term control.

Original languageEnglish
Article number102830
JournalCritical Reviews in Oncology/Hematology
Volume144
DOIs
Publication statusPublished - Dec 2019
Externally publishedYes

Fingerprint

Immunotherapy
Meta-Analysis
Radiotherapy
Neoplasm Metastasis
Brain
Neoplasms
Survival
PubMed
Melanoma
Safety
Therapeutics

Keywords

  • Brain metastases
  • Immunotherapy
  • Meta-analysis
  • Radiotherapy
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Combination of radiotherapy and immunotherapy for brain metastases : A systematic review and meta-analysis. / Petrelli, Fausto; De Stefani, Agostina; Trevisan, Francesca; Parati, Chiara; Inno, Alessandro; Merelli, Barbara; Ghidini, Michele; Bruschieri, Lorenza; Vitali, Elisabetta; Cabiddu, Mary; Borgonovo, Karen; Ghilardi, Mara; Barni, Sandro; Ghidini, Antonio.

In: Critical Reviews in Oncology/Hematology, Vol. 144, 102830, 12.2019.

Research output: Contribution to journalReview article

Petrelli, F, De Stefani, A, Trevisan, F, Parati, C, Inno, A, Merelli, B, Ghidini, M, Bruschieri, L, Vitali, E, Cabiddu, M, Borgonovo, K, Ghilardi, M, Barni, S & Ghidini, A 2019, 'Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis', Critical Reviews in Oncology/Hematology, vol. 144, 102830. https://doi.org/10.1016/j.critrevonc.2019.102830
Petrelli, Fausto ; De Stefani, Agostina ; Trevisan, Francesca ; Parati, Chiara ; Inno, Alessandro ; Merelli, Barbara ; Ghidini, Michele ; Bruschieri, Lorenza ; Vitali, Elisabetta ; Cabiddu, Mary ; Borgonovo, Karen ; Ghilardi, Mara ; Barni, Sandro ; Ghidini, Antonio. / Combination of radiotherapy and immunotherapy for brain metastases : A systematic review and meta-analysis. In: Critical Reviews in Oncology/Hematology. 2019 ; Vol. 144.
@article{33a0fb51d8b24680b8f58bf4df1b1538,
title = "Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis",
abstract = "Radiotherapy (RT) represents a mainstay in the treatment of brain metastases (BMs) from solid tumors. Immunotherapy (IT) has improved survival of metastatic cancer patients across many tumor types. The combination of RT and IT for the treatment of BMs has a strong rationale, but data on efficacy and safety of this combination is still limited. A systematic search of PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE was conducted. 33 studies were included for a total of 1520 patients, most of them with melanoma (87{\%}). Median pooled OS was 15.9 months (95{\%}CI 13.9–18.1). One- and 2-year OS rates were 55.2{\%} (95{\%} CI 49.3–60.9) and 35.7{\%} (95{\%} CI 30.4–41.3), respectively. Addition of IT to RT was associated with improved OS (HR = 0.54, 95{\%}CI 0.44-0.67; P < 0.001). For patients with BMs from solid tumors, addition of concurrent IT to brain RT is able to increase survival and provide long term control.",
keywords = "Brain metastases, Immunotherapy, Meta-analysis, Radiotherapy, Survival",
author = "Fausto Petrelli and {De Stefani}, Agostina and Francesca Trevisan and Chiara Parati and Alessandro Inno and Barbara Merelli and Michele Ghidini and Lorenza Bruschieri and Elisabetta Vitali and Mary Cabiddu and Karen Borgonovo and Mara Ghilardi and Sandro Barni and Antonio Ghidini",
year = "2019",
month = "12",
doi = "10.1016/j.critrevonc.2019.102830",
language = "English",
volume = "144",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Combination of radiotherapy and immunotherapy for brain metastases

T2 - A systematic review and meta-analysis

AU - Petrelli, Fausto

AU - De Stefani, Agostina

AU - Trevisan, Francesca

AU - Parati, Chiara

AU - Inno, Alessandro

AU - Merelli, Barbara

AU - Ghidini, Michele

AU - Bruschieri, Lorenza

AU - Vitali, Elisabetta

AU - Cabiddu, Mary

AU - Borgonovo, Karen

AU - Ghilardi, Mara

AU - Barni, Sandro

AU - Ghidini, Antonio

PY - 2019/12

Y1 - 2019/12

N2 - Radiotherapy (RT) represents a mainstay in the treatment of brain metastases (BMs) from solid tumors. Immunotherapy (IT) has improved survival of metastatic cancer patients across many tumor types. The combination of RT and IT for the treatment of BMs has a strong rationale, but data on efficacy and safety of this combination is still limited. A systematic search of PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE was conducted. 33 studies were included for a total of 1520 patients, most of them with melanoma (87%). Median pooled OS was 15.9 months (95%CI 13.9–18.1). One- and 2-year OS rates were 55.2% (95% CI 49.3–60.9) and 35.7% (95% CI 30.4–41.3), respectively. Addition of IT to RT was associated with improved OS (HR = 0.54, 95%CI 0.44-0.67; P < 0.001). For patients with BMs from solid tumors, addition of concurrent IT to brain RT is able to increase survival and provide long term control.

AB - Radiotherapy (RT) represents a mainstay in the treatment of brain metastases (BMs) from solid tumors. Immunotherapy (IT) has improved survival of metastatic cancer patients across many tumor types. The combination of RT and IT for the treatment of BMs has a strong rationale, but data on efficacy and safety of this combination is still limited. A systematic search of PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE was conducted. 33 studies were included for a total of 1520 patients, most of them with melanoma (87%). Median pooled OS was 15.9 months (95%CI 13.9–18.1). One- and 2-year OS rates were 55.2% (95% CI 49.3–60.9) and 35.7% (95% CI 30.4–41.3), respectively. Addition of IT to RT was associated with improved OS (HR = 0.54, 95%CI 0.44-0.67; P < 0.001). For patients with BMs from solid tumors, addition of concurrent IT to brain RT is able to increase survival and provide long term control.

KW - Brain metastases

KW - Immunotherapy

KW - Meta-analysis

KW - Radiotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85074787165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074787165&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2019.102830

DO - 10.1016/j.critrevonc.2019.102830

M3 - Review article

AN - SCOPUS:85074787165

VL - 144

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

M1 - 102830

ER -